The potential role of antioxidants in metabolic syndrome

Current Pharmaceutical Design

Volumn 22, Issue 7, 2016, Pages 859-869

  Gregório, Bianca Martins ^a   De Souza, Diogo Benchimol ^a   De Morais Nascimento, Fernanda Amorim ^b   Matta, Leonardo ^a   Fernandes Santos, Caroline ^c  

^a STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Antioxidants; Arginine; Carotenoids; Metabolic syndrome; Oxidative stress; Resveratrol; Selenium; Vitamins

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ARGININE; ASCORBIC ACID; CAROTENOID; FLAVONOID; RESVERATROL; SELENIUM;

ARTICLE; CACAO; CELL FUNCTION; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG DESIGN; DRUG EFFECT; HUMAN; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; TEA; ULTRAVIOLET RADIATION; ANIMAL; ATHEROSCLEROSIS; DIETARY SUPPLEMENT; DISEASE COURSE; DRUG EFFECTS; INFLAMMATION; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; ANTIOXIDANTS; ATHEROSCLEROSIS; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; HUMANS; INFLAMMATION; METABOLIC SYNDROME X; OXIDATION-REDUCTION; OXIDATIVE STRESS; RISK FACTORS;

EID: 84958554780     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666151209152352     Document Type: Article

References (161)

1. Polsky S, Ellis SL. Obesity, insulin resistance, and type 1 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 2015; 22: 277-82.
2. Welty FK, Alfaddagh A, Elajami TK. Targeting inflammation in metabolic syndrome. Transl Res 2016; 167(1): 257-80.
3. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009; 120: 1640-5.
4. Edwardson CL, Gorely T, Davies MJ, et al. Association of sedentary behaviour with metabolic syndrome: a meta-analysis. PLoS One 2012; 7: e34916.
5. Sun K, Ren M, Liu D, et al. Alcohol consumption and risk of metabolic syndrome: a meta-analysis of prospective studies. Clin Nutr 2013; 33: 596-602.
6. Limberg JK, Harrell JW, Johansson RE, et al. Microvascular function in younger adults with obesity and metabolic syndrome: role of oxidative stress. Am J Physiol Heart Circ Physiol 2013; 305: H1230-7.
7. Pham-Huy LA, He H, Pham-Huy C. Free radicals, antioxidants in disease and health. Int J Biomed Sci 2008; 4: 89-96.
8. Ishikawa S, Kayaba K, Gotoh T, et al. Metabolic syndrome and Creactive protein in the general population: JMS Cohort Study. Circ J 2007; 71: 26-31.
9. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997; 82: 291-5.
10. Soory M. Nutritional antioxidants and their applications in cardiometabolic diseases. Infect Disord Drug Targets 2012; 12: 388-401.
11. Czernichow S, Vergnaud AC, Galan P, et al. Effects of long-term antioxidant supplementation and association of serum antioxidant concentrations with risk of metabolic syndrome in adults. Am J Clin Nutr 2009; 90: 329-35.
12. Roberts CK, Sindhu KK. Oxidative stress and metabolic syndrome. Life sciences 2009; 22; 84: 705-12.
13. Majewska-Wierzbicka M, Czeczot H. Flavonoids in the prevention and treatment of cardiovascular diseases. Pol Merkur Lekarski 2012; 32: 50-4.
14. Kozlowska A, Szostak-Wegierek D. Flavonoids-food sources and health benefits. Rocz Panstw Zakl Hig 2014; 65: 79-85.
15. Egert S, Bosy-Westphal A, Seiberl J, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled crossover study. Br J Nutr 2009; 102: 1065-74.
16. Calderon-Montano JM, Burgos-Moron E, Perez-Guerrero C, et al. A review on the dietary flavonoid kaempferol. Mini Rev Med Chem 2011; 11: 298-344.
17. Shukla S, Gupta S. Apigenin: a promising molecule for cancer prevention. Pharm Res 2010; 27: 962-78.
18. Weng CJ, Yen GC. Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo antimetastatic activities. Cancer Metastasis Rev 2012; 31: 323-51.
19. Seelinger G, Merfort I, Schempp CM. Anti-oxidant, antiinflammatory and anti-allergic activities of luteolin. Planta Med 2008; 74: 1667-77.
20. Alam MA, Subhan N, Rahman MM, et al. Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. Adv Nutr 2014; 5: 404-17.
21. Pu P, Gao DM, Mohamed S, et al. Naringin ameliorates metabolic syndrome by activating AMP-activated protein kinase in mice fed a high-fat diet. Arch Biochem Biophys 2012; 518: 61-70.
22. Alam MA, Kauter K, Brown L. Naringin improves diet-induced cardiovascular dysfunction and obesity in high carbohydrate, high fat diet-fed rats. Nutrients 2013; 5: 637-50.
23. Kannappan S, Anuradha CV. Naringenin enhances insulinstimulated tyrosine phosphorylation and improves the cellular actions of insulin in a dietary model of metabolic syndrome. Eur J Nutr 2010; 49: 101-9.
24. Rizza S, Muniyappa R, Iantorno M, et al. Citrus polyphenol hesperidin stimulates production of nitric oxide in endothelial cells while improving endothelial function and reducing inflammatory markers in patients with metabolic syndrome. J Clin Endocrinol Metab 2011; 96: E782-92.
25. Khokhar S, Magnusdottir SG. Total phenol, catechin, and caffeine contents of teas commonly consumed in the United kingdom. J Agric Food Chem 2002; 50: 565-70.
26. Sano M, Tabata M, Suzuki M, et al. Simultaneous determination of twelve tea catechins by high-performance liquid chromatography with electrochemical detection. Analyst 2001; 126(6): 816-20.
27. Ikeda I. Multifunctional effects of green tea catechins on prevention of the metabolic syndrome. Asia Pac J Clin Nutr 2008; 17 Suppl 1: 273-4.
28. Basu A, Sanchez K, Leyva MJ, et al. Green tea supplementation affects body weight, lipids, and lipid peroxidation in obese subjects with metabolic syndrome. J Am Coll Nutr 2010; 29: 31-40.
29. Basu A, Du M, Sanchez K, et al. Green tea minimally affects biomarkers of inflammation in obese subjects with metabolic syndrome. Nutrition 2011; 27: 206-13.
30. Basu A, Betts NM, Mulugeta A, et al. Green tea supplementation increases glutathione and plasma antioxidant capacity in adults with the metabolic syndrome. Nutr Res 2013; 33: 180-7.
31. Chacko SM, Thambi PT, Kuttan R, et al. Beneficial effects of green tea: A literature review. Chin Med 2010; 5: 13.
32. Grassi D, Desideri G, Necozione S, et al. Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J Nutr 2008; 138: 1671-6.
33. Grassi D, Lippi C, Necozione S, et al. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr 2005; 81: 611-4.
34. Mursu J, Voutilainen S, Nurmi T, et al. Dark chocolate consumption increases HDL cholesterol concentration and chocolate fatty acids may inhibit lipid peroxidation in healthy humans. Free Radic Biol Med 2004; 37: 1351-9.
35. Almoosawi S, Tsang C, Ostertag LM, et al. Differential effect of polyphenol-rich dark chocolate on biomarkers of glucose metabolism and cardiovascular risk factors in healthy, overweight and obese subjects: a randomized clinical trial. Food Funct 2012; 3: 1035-43.
36. Wang-Polagruto JF, Villablanca AC, Polagruto JA, et al. Chronic consumption of flavanol-rich cocoa improves endothelial function and decreases vascular cell adhesion molecule in hypercholesterolemic postmenopausal women. J Cardiovasc Pharmacol 2006; 47 (Suppl 2): S177-86; discussion S206-9.
37. Davison K, Howe P. Potential implications of dose and diet for the effects of cocoa flavanols on cardio-metabolic function. J Agric Food Chem 2015; 63(45): 9942-7.
38. Tokede OA, Ellison CR, Pankow JS, et al. Chocolate consumption and prevalence of metabolic syndrome in the NHLBI Family Heart Study. ESPEN J 2012; 7: e139-e43.
39. Acquaviva R, Russo A, Galvano F, et al. Cyanidin and cyanidin 3-O-beta-D-glucoside as DNA cleavage protectors and antioxidants. Cell Biol Toxicol 2003; 19: 243-52.
40. Ramirez-Tortosa C, Andersen OM, Cabrita L, et al. Anthocyaninrich extract decreases indices of lipid peroxidation and DNA damage in vitamin E-depleted rats. Free Radic Biol Med 2001; 31: 1033-7.
41. Rossi A, Serraino I, Dugo P, et al. Protective effects of anthocyanins from blackberry in a rat model of acute lung inflammation. Free Radic Res 2003; 37: 891-900.
42. Lila MA. Anthocyanins and human health: an in vitro investigative approach. J Biomed Biotechnol 2004; 2004: 306-13.
43. Prior RL, Cao G, Martin A, et al. Antioxidant capacity as influenced by total phenolic and anthocyanin content, maturity, and variety of vaccinium species. J Agric Food Chem 1998; 46(7): 2686-93.
44. Basu A, Du M, Leyva MJ, et al. Blueberries decrease cardiovascular risk factors in obese men and women with metabolic syndrome. J Nutr 2010; 140: 1582-7.
45. Basu A, Fu DX, Wilkinson M, et al. Strawberries decrease atherosclerotic markers in subjects with metabolic syndrome. Nutr Res 2010; 30: 462-9.
46. Pilsakova L, Riecansky I, Jagla F. The physiological actions of isoflavone phytoestrogens. Physiol Res 2010; 59: 651-64.
47. Acharjee S, Zhou JR, Elajami TK, et al. Effect of soy nuts and equol status on blood pressure, lipids and inflammation in postmenopausal women stratified by metabolic syndrome status. Metabolism 2015; 64: 236-43.
48. Irace C, Marini H, Bitto A, et al. Genistein and endothelial function in postmenopausal women with metabolic syndrome. Eur J Clin Invest 2013; 43: 1025-31.
49. Squadrito F, Marini H, Bitto A, et al. Genistein in the metabolic syndrome: results of a randomized clinical trial. J Clin Endocrinol Metab 2013; 98: 3366-74.
50. Schulze ES. Ueber einen neuen stickstoffhaltigen bestandtheil der keimlinge von lupinus luteus. Berichte der deutschen chemischen Gesellschaft 1886; 19: 1177-80.
51. Hird FJ, Mclean SC, McLean RM. Investigations on the origin and metabolism of the carbon skeleton of ornithine, arginine and proline in selected animals. Comp Biochem Physiol B 1986; 83(1): 179-84.
52. Palmer DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333: 664-6.
53. Schmidt HH, Nau H, Wittfoht W, et al. Arginine is a physiological precursor of endothelium-derived nitric oxide. Eur J Pharmacol 1988; 154: 213-6.
54. Lucotti P, Setola E, Monti LD, et al. Beneficial effects of a longterm oral L-arginine treatment added to a hypocaloric diet and exercise training program in obese, insulin-resistant type 2 diabetic patients. Am J Physiol Endocrinol Metab 2006; 291: E906-12.
55. Mendez JD, Balderas F. Regulation of hyperglycemia and dyslipidemia by exogenous L-arginine in diabetic rats. Biochimie 2001; 83: 453-8.
56. Jobgen W, Fu WJ, Gao H, et al. High fat feeding and dietary Larginine supplementation differentially regulate gene expression in rat white adipose tissue. Amino Acids 2009; 37: 187-98.
57. Fu WJ, Haynes TE, Kohli R, et al. Dietary L-arginine supplementation reduces fat mass in Zucker diabetic fatty rats. J Nutr 2005; 135: 714-21.
58. Schmidt HH, Warner TD, Ishii K, et al. Insulin secretion from pancreatic B cells caused by L-arginine-derived nitrogen oxides. Science 1992; 255: 721-3.
59. Schmidt HH, Lohmann SM, Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochim Biophys Acta 1993; 1178: 153-75.
60. Kimura H, Mittal CK, Murad F. Activation of guanylate cyclase from rat liver and other tissues by sodium azide. J Biol Chem 1975; 250: 8016-22.
61. McKnight JR, Satterfield MC, Jobgen WS, et al. Beneficial effects of L-arginine on reducing obesity: potential mechanisms and important implications for human health. Amino Acids 2010; 39: 349-57.
62. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag 2007; 3: 853-76.
63. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 1999; 31: 61-74.
64. Nematbakhsh M, Haghjooyjavanmard S, Mahmoodi F, et al. The prevention of endothelial dysfunction through endothelial cell apoptosis inhibition in a hypercholesterolemic rabbit model: the effect of L-arginine supplementation. Lipids Health Dis 2008; 7: 27.
65. Lekakis JP, Papathanassiou S, Papaioannou TG, et al. Oral Larginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol 2002; 86: 317-23.
66. Yin WH, Chen JW, Tsai C, et al. L-arginine improves endothelial function and reduces LDL oxidation in patients with stable coronary artery disease. Clin Nutr 2005; 24: 988-97.
67. King CG, Waugh WA. The chemical nature of vitamin C. Science 1932; 75: 357-8.
68. Vilter RW. Nutritional aspects of ascorbic acid: uses and abuses. West J Med 1980; 133: 485-92.
69. Arrigoni O, De Tullio MC. Ascorbic acid: much more than just an antioxidant. Biochim Biophys Acta 2002; 1569: 1-9.
70. May JM, Harrison FE. Role of vitamin C in the function of the vascular endothelium. Antioxid Redox Signal 2013; 19: 2068-83.
71. Garcia-Diaz DF, Lopez-Legarrea P, Quintero P, et al. Vitamin C in the treatment and/or prevention of obesity. J Nutr Sci Vitaminol (Tokyo) 2014; 60: 367-79.
72. Wilson JX. The physiological role of dehydroascorbic acid. FEBS Lett 2002; 527: 5-9.
73. Shaik-Dasthagirisaheb YB, Varvara G, Murmura G, et al. Role of vitamins D, E and C in immunity and inflammation. J Biol Regul Homeost Agents 2013; 27: 291-5.
74. Oudemans-van Straaten HM, Spoelstra-de Man AM, de Waard MC. Vitamin C revisited. Crit Care 2014; 18: 460.
75. Wei J, Zeng C, Gong QY, et al. Associations between dietary antioxidant intake and metabolic syndrome. PLoS One 2015; 10: e0130876.
76. Ford ES, Mokdad AH, Giles WH, et al. The metabolic syndrome and antioxidant concentrations: findings from the Third National Health and Nutrition Examination Survey. Diabetes 2003; 52: 2346-52.
77. Golbidi S, Ebadi SA, Laher I. Antioxidants in the treatment of diabetes. Curr Diabetes Rev 2011; 7: 106-25.
78. Franke SI, Muller LL, Santos MC, et al. Vitamin C intake reduces the cytotoxicity associated with hyperglycemia in prediabetes and type 2 diabetes. Biomed Res Int 2013; 2013: 896536.
79. Carter P, Gray LJ, Talbot D, et al. Fruit and vegetable intake and the association with glucose parameters: a cross-sectional analysis of the Let's prevent diabetes study. Eur J Clin Nutr 2013; 67: 12-7.
80. Garcia-Diaz DF, Campion J, Milagro FI, et al. Ascorbic acid oral treatment modifies lipolytic response and behavioural activity but not glucocorticoid metabolism in cafeteria diet-fed rats. Acta Physiol (Oxf) 2009; 195: 449-57.
81. Levine M, Padayatty SJ, Espey MG. Vitamin C: a concentrationfunction approach yields pharmacology and therapeutic discoveries. Adv Nutr 2011; 2: 78-88.
82. Taylor EN, Stampfer MJ, Curhan GC. Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol 2004; 15: 3225-32.
83. Garcia-Diaz DF, Campion J, Milagro FI, et al. Vitamin C inhibits leptin secretion and some glucose/lipid metabolic pathways in primary rat adipocytes. J Mol Endocrinol 2010; 45: 33-43.
84. Garcia-Diaz DF, Campion J, Quintero P, et al. Vitamin C modulates the interaction between adipocytes and macrophages. Mol Nutr Food Res 2011; 55 Suppl 2: S257-63.
85. Milagro FI, Campion J, Martinez JA. Weight gain induced by highfat feeding involves increased liver oxidative stress. Obesity (Silver Spring) 2006; 14: 1118-23.
86. Hodgson JM, Croft KD, Woodman RJ, et al. Effects of vitamin E, vitamin C and polyphenols on the rate of blood pressure variation: results of two randomised controlled trials. Br J Nutr 2014; 112: 1551-61.
87. Leopold JA. Antioxidants and coronary artery disease: from pathophysiology to preventive therapy. Coron Artery Dis 2015; 26: 176-83.
88. Wallert M, Schmolz L, Galli F, et al. Regulatory metabolites of vitamin E and their putative relevance for atherogenesis. Redox Biol 2014; 2: 495-503.
89. Devaraj S, Leonard S, Traber MG, et al. Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radical Biol Med 2008; 44: 1203-8.
90. Fang F, Kang Z, Wong C. Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors. Mol Nutr Food Res 2010; 54: 345-52.
91. Shelton NW, Dritz SS, Nelssen JL, et al. Effects of dietary vitamin E concentration and source on sow, milk, and pig concentrations of alpha-tocopherol. J Anim Sci 2014; 92: 4547-56.
92. Dietrich M, Traber MG, Jacques PF, et al. Does gamma-tocopherol play a role in the primary prevention of heart disease and cancer? A review. J Am College Nutr 2006; 25: 292-9.
93. Monsen ER. Dietary reference intakes for the antioxidant nutrients: vitamin C, vitamin E, selenium, and carotenoids. J Am Diet Assoc 2000; 100: 637-40.
94. Ashor AW, Siervo M, Lara J, et al. Effect of vitamin C and vitamin E supplementation on endothelial function: a systematic review and meta-analysis of randomised controlled trials. Br J Nutr 2015; 113: 1182-94.
95. Kim do Y, Kim J, Ham HJ, et al. Effects of d-alpha-tocopherol supplements on lipid metabolism in a high-fat diet-fed animal model. Nutr Res Pract 2013; 7: 481-7.
96. Landrier JF, Gouranton E, El Yazidi C, et al. Adiponectin expression is induced by vitamin E via a peroxisome proliferator-activated receptor gamma-dependent mechanism. Endocrinology 2009; 150: 5318-25.
97. Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (Adi-Pose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-9.
98. Gray B, Swick J, Ronnenberg AG. Vitamin E and adiponectin: proposed mechanism for vitamin E-induced improvement in insulin sensitivity. Nutr Rev 2011; 69: 155-61.
99. Rao AV, Rao LG. Carotenoids and human health. Pharmacol Res 2007; 55: 207-16.
100. Mangels AR, Holden JM, Beecher GR, et al. Carotenoid content of fruits and vegetables: an evaluation of analytic data. J Am Diet Assoc 1993; 93: 284-96.
101. Olson JA, Hayaishi O. The enzymatic cleavage of beta-carotene into vitamin A by soluble enzymes of rat liver and intestine. Proc Natl Acad Sci USA 1965; 54: 1364-70.
102. Sies H, Stahl W. Non-nutritive bioactive constituents of plants: lycopene, lutein and zeaxanthin. Int J Vitam Nutr Res 2003; 73: 95-100.
103. Park S, Ham JO, Lee BK. Effects of total vitamin A, vitamin C, and fruit intake on risk for metabolic syndrome in Korean women and men. Nutrition (Burbank, Los Angeles County, Calif) 2015; 31: 111-8.
104. Coyne T, Ibiebele TI, Baade PD, et al. Diabetes mellitus and serum carotenoids: findings of a population-based study in Queensland, Australia. Am J Clin Nutr 2005; 82: 685-93.
105. Ylonen K, Alfthan G, Groop L, et al. Dietary intakes and plasma concentrations of carotenoids and tocopherols in relation to glucose metabolism in subjects at high risk of type 2 diabetes: the Botnia Dietary Study. Am J Clin Nutr 2003; 77: 1434-41.
106. Liu J, Shi WQ, Cao Y, et al. Higher serum carotenoid concentrations associated with a lower prevalence of the metabolic syndrome in middle-aged and elderly Chinese adults. Br J Nutr 2014; 112: 2041-8.
107. Suzuki K, Ito Y, Inoue T, et al. Inverse association of serum carotenoids with prevalence of metabolic syndrome among Japanese. Clin Nutr 2011; 30: 369-75.
108. Andersen LF, Jacobs DR Jr, Gross MD, et al. Longitudinal associations between body mass index and serum carotenoids: the CARDIA study. Br J Nutr 2006; 95: 358-65.
109. Galan P, Viteri FE, Bertrais S, et al. Serum concentrations of betacarotene, vitamins C and E, zinc and selenium are influenced by sex, age, diet, smoking status, alcohol consumption and corpulence in a general French adult population. Eur J Clin Nutr 2005; 59: 1181-90.
110. Kimmons JE, Blanck HM, Tohill BC, et al. Associations between body mass index and the prevalence of low micronutrient levels among US adults. Med Gen Med 2006; 8: 59.
111. Sugiura M, Nakamura M, Ogawa K, et al. Associations of serum carotenoid concentrations with the metabolic syndrome: interaction with smoking. Br J Nutr 2008; 100: 1297-306.
112. Barona J, Jones JJ, Kopec RE, et al. A Mediterranean-style lowglycemic-load diet increases plasma carotenoids and decreases LDL oxidation in women with metabolic syndrome. J Nutr Biochem 2012; 23: 609-15.
113. Valtuena S, Del Rio D, Pellegrini N, et al. The total antioxidant capacity of the diet is an independent predictor of plasma betacarotene. Eur J Clin Nutr 2007; 61: 69-76.
114. Ben Amara N, Tourniaire F, Maraninchi M, et al. Independent positive association of plasma beta-carotene concentrations with adiponectin among non-diabetic obese subjects. Eur J Nutr 2015; 54: 447-54.
115. Landrier JF, Marcotorchino J, Tourniaire F. Lipophilic micronutrients and adipose tissue biology. Nutrients 2012; 4: 1622-49.
116. Chung HY, Ferreira AL, Epstein S, et al. Site-specific concentrations of carotenoids in adipose tissue: relations with dietary and serum carotenoid concentrations in healthy adults. Am J Clin Nutr 2009; 90: 533-9.
117. Liu S, Ajani U, Chae C, et al. Long-term β-carotene supplementation and risk of type 2 diabetes mellitus: a randomized controlled trial. JAMA 2015; 282: 1073-5.
118. Tornwall ME, Virtamo J, Haukka JK, et al. The effect of alphatocopherol and beta-carotene supplementation on symptoms and progression of intermittent claudication in a controlled trial. Atherosclerosis 1999; 147: 193-7.
119. Asplund K. Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review. J Intern Med 2002; 251: 372-92.
120. Vivekananthan DP, Penn MS, Sapp SK, et al. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet (London, England) 2003; 361: 2017-23.
121. Iwamoto M, Imai K, Ohta H, et al. Supplementation of highly concentrated beta-cryptoxanthin in a satsuma mandarin beverage improves adipocytokine profiles in obese Japanese women. Lipids Health Dis 2012; 11: 52.
122. Titov VN. Leptin and adiponectin in pathogenesis of metabolic syndrome. Klinicheskaia Med 2014; 92: 20-9.
123. Dan T, Ichimura A, Pelisch N, et al. Plasminogen activator inhibitor-1 (PAI-1) molecule: new physiological roles and clinical applications. [Rinsho ketsueki] Japanese J Clin Hematol 2014; 55: 396-404.
124. Tsitsimpikou C, Tsarouhas K, Kioukia-Fougia N, et al. Dietary supplementation with tomato-juice in patients with metabolic syndrome: a suggestion to alleviate detrimental clinical factors. Food Chem Toxicol 2014; 74: 9-13.
125. Kim SM, Jung YJ, Kwon ON, et al. A potential commercial source of fucoxanthin extracted from the microalga Phaeodactylum tricornutum. Appl Biochem Biotechnol 2012; 166: 1843-55.
126. Maeda H, Hosokawa M, Sashima T, et al. Dietary combination of fucoxanthin and fish oil attenuates the weight gain of white adipose tissue and decreases blood glucose in obese/diabetic KK-Ay mice. J Agric Food Chem 2007; 55: 7701-6.
127. Sangeetha RK, Bhaskar N, Baskaran V. Comparative effects of beta-carotene and fucoxanthin on retinol deficiency induced oxidative stress in rats. Mol Cellular Biochem 2009; 331: 59-67.
128. Woo MN, Jeon SM, Kim HJ, et al. Fucoxanthin supplementation improves plasma and hepatic lipid metabolism and blood glucose concentration in high-fat fed C57BL/6N mice. Chem Biol Interact 2010; 186: 316-22.
129. Lorenz RT, Cysewski GR. Commercial potential for Haematococcus microalgae as a natural source of astaxanthin. Trends Biotechnol 2000; 18: 160-7.
130. Hussein G, Nakagawa T, Goto H, et al. Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp. Life Sci 2007; 80: 522-9.
131. Ikeuchi M, Koyama T, Takahashi J, et al. Effects of astaxanthin in obese mice fed a high-fat diet. Biosci Biotechnol Biochem 2007; 71: 893-9.
132. Nonomura S, Kanagawa H, Makimoto A. Chemical Constituents of Polygonaceous Plants. I. Studies on the Components of Ko-J OKon. (Polygonum Cuspidatum Sieb. Et Zucc.). Yakugaku Zasshi 1963; 83: 988-90.
133. Szkudelska K, Szkudelski T. Resveratrol, obesity and diabetes. Eur J Pharmacol 2010; 635: 1-8.
134. Inoue H, Nakata R. Resveratrol targets in inflammation. Endocr Metab Immune Disord Drug Targets 2015.
135. Siemann EHaC L.L. Concentration of the phytoalexin resveratrol in wine. Am J Enol Viticulture 1992; 43: 49-52.
136. Singh CK, Ndiaye MA, Ahmad N. Resveratrol and cancer: Challenges for clinical translation. Biochim Biophys Acta 2015; 1852: 1178-85.
137. Tung BT, Rodriguez-Bies E, Talero E, et al. Anti-inflammatory effect of resveratrol in old mice liver. Exp Gerontol 2015; 64: 1-7.
138. Boydens C, Pauwels B, Decaluwe K, et al. Relaxant and antioxidant capacity of the red wine polyphenols, resveratrol and quercetin, on isolated mice corpora cavernosa. J Sex Med 2015; 12: 303-12.
139. Zagotta I, Dimova EY, Debatin KM, et al. Obesity and inflammation: reduced cytokine expression due to resveratrol in a human in vitro model of inflamed adipose tissue. Front Pharmacol 2015; 6: 79.
140. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-42.
141. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127: 1109-22.
142. Rocha KK, Souza GA, Ebaid GX, et al. Resveratrol toxicity: effects on risk factors for atherosclerosis and hepatic oxidative stress in standard and high-fat diets. Food Chem Toxicol 2009; 47: 1362-7.
143. Zhang Y, Jayaprakasam B, Seeram NP, et al. Insulin secretion and cyclooxygenase enzyme inhibition by cabernet sauvignon grape skin compounds. J Agric Food Chem 2004; 52: 228-33.
144. Hambrock A, de Oliveira Franz CB, Hiller S, et al. Resveratrol binds to the sulfonylurea receptor (SUR) and induces apoptosis in a SUR subtype-specific manner. J Biol Chem 2007; 282: 3347-56.
145. Albertoni G, Schor N. Resveratrol plays important role in protective mechanisms in renal disease--mini-review. J Bras Nefrol 2015; 37: 106-14.
146. Zhang H, Zhang J, Ungvari Z, et al. Resveratrol improves endothelial function: role of TNF{alpha} and vascular oxidative stress. Arterioscler Thromb Vasc Biol 2009; 29: 1164-71.
147. Spanier G, Xu H, Xia N, et al. Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4). J Physiol Pharmacol 2009; 60 Suppl 4: 111-6.
148. Rayman MP. Food-chain selenium and human health: emphasis on intake. Br J Nutr 2008; 100: 254-68.
149. Alissa EM, Bahijri SM, Ferns GA. The controversy surrounding selenium and cardiovascular disease: a review of the evidence. Med Sci Monit 2003; 9: RA9-18.
150. Schrauzer GN, Surai PF. Selenium in human and animal nutrition: resolved and unresolved issues. A partly historical treatise in commemoration of the fiftieth anniversary of the discovery of the biological essentiality of selenium, dedicated to the memory of Klaus Schwarz (1914-1978) on the occasion of the thirtieth anniversary of his death. Crit Rev Biotechnol 2009; 29: 2-9.
151. Thomson CD, Chisholm A, McLachlan SK, et al. Brazil nuts: an effective way to improve selenium status. Am J Clin Nutr 2008; 87: 379-84.
152. Wei WQ, Abnet CC, Qiao YL, et al. Prospective study of serum selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death. Am J Clin Nutr 2004; 79: 80-5.
153. Fritzen AM, Lundsgaard AM, Jordy AB, et al. New Nordic Diet induced weight loss is accompanied by changes in metabolism and AMPK signalling in adipose tissue. J Clin Endocrinol Metabol 2015; 100(9): 3509-19.
154. Kolehmainen M, Ulven SM, Paananen J, et al. Healthy Nordic diet downregulates the expression of genes involved in inflammation in subcutaneous adipose tissue in individuals with features of the metabolic syndrome. Am J Clin Nutr 2015; 101: 228-39.
155. Sedighi O, Makhlough A, Shokrzadeh M, et al. Association between plasma selenium and glutathione peroxidase levels and severity of diabetic nephropathy in patients with type two diabetes mellitus. Nephrourol Mon 2014; 6: e21355.
156. Farvid MS, Jalali M, Siassi F, et al. Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. Diabetes Care 2005; 28: 2458-64.
157. Wei J, Zeng C, Gong QY, et al. The association between dietary selenium intake and diabetes: a cross-sectional study among middle-aged and older adults. Nutr J 2015; 14: 18.
158. Evans JL, Maddux BA, Goldfine ID. The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal 2005; 7: 1040-52.
159. Laclaustra M, Navas-Acien A, Stranges S, et al. Serum selenium concentrations and diabetes in U.S. adults: National Health and Nutrition Examination Survey (NHANES) 2003-2004. Environ Health Perspect 2009; 117: 1409-13.
160. Collins R, Johansson AL, Karlberg T, et al. Biochemical discrimination between selenium and sulfur 1: a single residue provides selenium specificity to human selenocysteine lyase. PLoS One 2012; 7: e30581.
161. Seale LA, Hashimoto AC, Kurokawa S, et al. Disruption of the selenocysteine lyase-mediated selenium recycling pathway leads to metabolic syndrome in mice. Mol Cell Biol 2012; 32: 4141-54.